Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors

Documenti analoghi

• In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure
  di: La Seta Catamancio, Simona, et al.
  Pubblicazione: (2001)
• Response to Antiretroviral Therapy in a Patient with an Uncommon Codon 69 Insertion in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase
  di: Bonfanti, Paolo, et al.
  Pubblicazione: (2000)
• Combination of CCR5 and CXCR4 Inhibitors in Therapy of Human Immunodeficiency Virus Type 1 Infection: In Vitro Studies of Mixed Virus Infections
  di: Rusconi, Stefano, et al.
  Pubblicazione: (2000)
• Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
  di: Poppe, S M, et al.
  Pubblicazione: (1997)
• Tipranavir in the Protease Inhibitors Arena
  di: Vergani, Barbara, et al.
  Pubblicazione: (2012)